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Abstract
Aromatase (CYP19) is a critical enzyme for estrogen biosynthesis, and aromatase inhibitors (AIs)
are established endocrine therapy for post-menopausal women with breast cancer. DNA samples
were obtained from 52 women pre- and post-AI treatment in the neoadjuvant setting. 82 breast cancer
and 19 normal breast samples were resequenced to test the hypothesis that single nucleotide
polymorphisms (SNPs) in the CYP19 gene might contribute to response to neoadjuvant AI therapy.
There were no differences in CYP19 sequence between tumor and germline DNA in the same patient.
Forty-eight CYP19 SNPs were identified, with four being novel when compared with previous
resequencing data. Genotype-phenotype association studies performed with levels of aromatase
activity, estrone, estradiol and tumor size pre- and post-AI treatment indicated that two tightly linked
SNPs, rs6493497 and rs7176005 in the 5’-flanking region of CYP19 exon 1.1, were significantly
associated with a greater change in aromatase activity after AI treatment. A follow-up study in 200
women with early breast cancer treated with adjuvant anastrozole showed that these same two SNPs
were also associated with higher plasma estradiol levels pre- and post-AI treatment. Electrophoretic
mobility shift and reporter gene assays confirmed the potential functional effects of these two SNPs
on transcription regulation. These studies provide insight into the role of common genetic
polymorphisms in CYP19 in variation in response to AIs by breast cancer patients.
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Introduction
In post-menopausal women, the major source of estrogen is the peripheral synthesis of estrone
and estradiol by the cytochrome P450 enzyme aromatase (CYP19A1). The third generation
aromatase inhibitors (AIs), anastrozole, exemestane, and letrozole, are potent and specific
inhibitors of aromatase (1,2) and have become established for the treatment of metastatic
disease (3) and as adjuvant therapy in early breast cancer (4). These three AIs have been studied
in the neo-adjuvant setting by two of the authors (WRM, JMD) and, in these 59 patients, 46
(78%) had a clinically determined major response, defined as >50% reduction in tumor volume,
8 (14%) had a 25-50% reduction in tumor volume and 5 (8%) had <25% reduction (5).
Selected CYP19 polymorphisms have been investigated for their possible association with the
therapeutic efficacy of aromatase inhibitors and with sex hormone levels or risk for estrogen-
dependent diseases (6-17). Although the results of those studies are controversial, they suggest
an important role for genetic variation in aromatase function and, as a result, in estrogen
production. Previously, we performed a CYP19 resequencing study with 240 germline DNA
samples from 4 ethnic groups to identify 88 common SNPs and 44 common haplotypes (18).
In this study, we investigated whether a difference in CYP19 sequence between breast tumor
and germline DNA might exist and whether SNPs in tumor CYP19 might have a significant
affect on response to AI therapy. Specifically, we obtained DNA samples isolated from breast
tumor and normal breast tissue from 52 Edinburgh women treated with AIs in a neoadjuvant
setting for which in vivo assays had been performed to measure levels of aromatase activity,
estrone (E1) and estradiol (E2) in the tumors as well as tumor size before and after AI treatment
(5). Gene resequencing was performed with DNA from both tumor and normal breast tissue
pre- and post-AI treatment. A genotype-phenotype association study was then performed with
the resequenced SNPs and all of the in vivo phenotypes. Functional genomic studies and a
follow-up study were also performed to confirm observations made during the initial genotype-
phenotype association study.
Material and Methods
Clinical samples and phenotype data
Both tumor and normal breast tissue samples were obtained from patients previously described
in detail (5). Specifically, women with ER-positive (defined as >20 fmol/mg cytosol protein)
primary breast cancer larger than 3 cm (stage T2,3,4b, N0,1, M0) and no prior treatment or
concurrent treatment with hormone preparations were recruited to a neoadjuvant study to assess
levels of E1, E2 and aromatase activity in the tumor, as well as tumor size pre- and post-AI
treatment. All patients had received either letrozole (2.5mg or 10mg daily), anastrozole (1mg
or 10mg daily) or exemestane (25mg daily). Patients in the study from whom the specimens
were obtained underwent tumor measurement before, at monthly intervals and at the end of
the 3 months of AI therapy. In addition, patients were given an infusion of 3H-androstenedione
and 14C-estrone before and at the end of the 3-month treatment period, with blood, tumor and
non-malignant breast tissue taken immediately after the infusion. That original study was
designed to determine the effect of neoadjuvant AI therapy on the tumor – while the present
study utilize those data to determine genotype-phenotype associations for CYP19
polymorphisms.
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DNA samples were isolated from 52 patients, including 19 from normal and 82 from tumor
tissue. 13 were normal-tumor pairs obtained from the same individuals. Tumor DNA included
pre- and post-AI treatment samples. After quality control for the gene resequencing results and
merging with clinical phenotypes, 77 DNA samples from 45 individuals were available for use
in the genotype-phenotype studies. Characteristics of these 45 patients are listed in
Supplementary Table 1. This clinical protocol was reviewed and approved by the Lothian
Research Ethics Committee, Edinburgh, UK and all participants provided written consent. The
genotyping study reported subsequently was reviewed and approved by the Mayo Institutional
Review Board.
Follow-up study sample sets
200 DNA samples were isolated from women treated with 1mg anastrozole per day in an
ongoing Mayo Clinic-MD Anderson collaborative clinical pharmacogenomic study. Plasma
samples were collected from these women to measure levels of E1 and E2 as well as anastrozole
concentrations. E1 and E2 levels pre- and post-treatment with anastrozole were measured by
a gas chromatographic negative ionization tandem mass spectrometry (GC/NCI/MS/MS) and
liquid chromatographic electrospray tandem mass spectrometry (LC/ESI/MS/MS)
bioanalytical method at Taylor Technology (Princeton, NJ). Anastrozole and anastrozole
metabolite levels were measured by an LC/MS/MS assay performed at Indiana University.
This protocol was reviewed and approved by the Mayo Clinic and MD Anderson Institutional
Review Boards, and all participants provided written consent.
CYP19 gene resequencing
Resequencing was performed using primers and PCR conditions listed in Supplementary Table
2. Resequenced regions included all coding exons, noncoding upstream exons, intron-exon
splice junctions, 1000 bp of 5’–flanking regions (5’-FRs) for each of the noncoding exons and
the 3’-untranslated region (3’-UTR). The primers and PCR conditions differed slightly from
our previous resequencing study using 240 ethnically defined DNA samples (18) in that we
sequenced longer regions than in the previous study. Because of this difference, we also
resequenced additional regions included in the present study using the same 60 Caucasian DNA
samples used in the previous study to allow us to directly compare the resequencing results
between germline DNA from healthy individuals and tumor DNA from breast cancer patients.
Amplicons were sequenced on both strands with an ABI 3730 DNA sequencer. Independent
amplifications were performed for samples in which a SNP was observed only once or for
samples with ambiguous chromatograms. The chromatograms were analyzed using Mutation
Surveyor (SoftGenetics, State College, PA).
Cell culture and transfection
A mammalian expression construct was created for Arg128 by performing site-directed
mutagenesis using the WT construct described previously (18) as template for circular PCR.
Primers used to perform mutagenesis are listed in Supplementary Table 3. COS-1 cells obtained
from ATCC (American Tissue Culture Center, Manassas, VA) were transfected with the WT
and variant CYP19 constructs as well as empty vector as control using the TranFast reagent
(Promega, Madison, WI). The pSV40-β-galactosidase vector encoding β-galactosidase
(Promega, Madison, WI) was used as a control for transfection efficiency.
Aromatase enzyme assay and inhibition study
Aromatase activity was determined as described previously (18-20). Specifically, microsomes
were isolated from COS-1 cells transfected with WT, Arg128 and empty vector together with
β-galactosidase. Microsomal preparations were then used to perform the aromatase enzyme
assay using [1β3H] androst-4-ene-3,17-dione (NEN Life Science Products, Boston, MA) as
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substrate (18). Aromatase activity was assayed by measuring the release of 3H2O from radio-
labeled substrate. Reactions were carried out for 45 minutes at 37°C with an NADPH
regeneration system in a final 100 μl volume as described previously. Blanks were samples
that lacked enzyme. For substrate kinetic studies, substrate concentrations ranged from 0 to
80nM. For inhibition studies, assays were performed in the presence of three concentrations
of letrozole (0.2, 0.4 and 0.8nM). Km and Kis values were then determined.
Electrophoresis mobility shift assay (EMSA)
Nuclear extracts from SKBR03 cells (ATCC) were isolated and protein was quantified with
the method of Bradford (21). Biotin labeled sense and anti-sense oligonucleotides were
designed to contain WT and variant sequences for the rs6493497 (G/A) and rs7176005 (C/T)
SNPs. Probe sequences are listed in Supplementary Table 3. EMSAs were performed with the
LightShift™ Chemiluminescent EMSA Kit (Pierce, Rockford, IL). A 400-fold excess of
unlabeled probe was added for the competition assays.
Reporter gene assay
Reporter gene constructs were created by PCR amplification of a 1000 bp region surrounding
the two SNPs using Coriell DNA as template. The WT PCR product was cloned into pGL3
Basic vector (Promega, Madison, WI) followed by mutagenesis to obtain the variant constructs.
Primers used to perform mutagenesis are listed in Supplementary Table 3. DNA sequences
were verified by sequencing both strands. Vector without an insert was used as a control.
SKBR03 cells were transfected with WT and variant constructs together with a pRL-TK DNA
construct encoding Renilla luciferase as a control for transfection efficiency. Cells were then
lyzed and luciferase activity was measured using a dual luciferase activity assay with a
TD-20/20 Luminometer (Turner Designs, Sunnyvale, CA). Results were reported as the ratio
of firefly luciferase to Renilla luciferase light units, and all values were expressed as a
percentage of the activity of the WT construct. All assays were performed in triplicate.
Taqman assay
In a follow-up study, SNPs rs6493497 (G/A) and rs7176005 (C/T), upstream of CYP19 exon
1.1, were genotyped using 200 germline DNA samples from breast cancer patients being treated
with adjuvant anastrozole. Taqman assays were performed according to the manufacturer's
instructions. Positive (Coriell DNA with known genotypes) and negative controls (lacking
DNA) were included in the assays.
Statistical methods
SNPs obtained during the gene resequencing study were subjected to quality control to remove
those with minor allele frequencies (MAFs) <5%, SNPs that deviated significantly from Hardy-
Weinberg equilibrium (HWE) (P<0.001) or with call rates <95%. Due to skewness of the
phenotypes, the van der Waerden rank normal score transformation was performed for all
phenotypes. Phenotypes were compared among anastrozole, exemestane, and letrozole using
a Monte Carlo approximated exact Krustal Wallis test. SNP associations with transformed
phenotypes were assessed using ordinary regression, treating genotype effect as the count of
minor alleles (i.e., 1df or trend test) in all treatment groups, as well in a subset analysis by
treatment group. For the genotypic analyses, p-values were corrected for multiple testing by a
permutation step-up procedure (22). Linkage disequilibrium among CYP19 polymorphisms
was determined by calculating D' and R2 values for all possible pairwise combinations of
polymorphisms, and the data were plotted using Haploview software (23). Haplotypes were
estimated for the markers passing QC and compared among phenotypes using score tests from
the haplo.stats software
(http://mayoresearch.mayo.edu/mayo/research/schaid_lab/software.cfm) (24). For the follow-
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up study, the relationship between genotypes and pre- and post-drug E1 and E2 concentrations
were modeled using a negative bimodal generalized linear model due to the extreme skewness
of the phenotypes (25,26). Models of post-treatment E1 and E2 were also adjusted for
anastrozole levels. Differences in E1 and E2, pre- to post-treatment, were left on their original
scale. Ordinary regression was used to assess the association of phenotypes and genotypes
treated as the count of minor alleles (i.e. 1df).
Differences in enzyme activity, protein levels and luciferase activities were tested using
Student's T-test within the software prism. Ki and Km values were calculated with the Prism
Program.
Results
CYP19 gene resequencing
CYP19 resequencing identified 48 SNPs (Figure 1 and Supplementary Table 4). No differences
were observed between normal germline and tumor DNA. Since one reaction covering part of
the 5’-FR of exon 1.7 contained two indels, one located 1051 bp and the other 1000 bp upstream
of exon 1.7, respectively, we could not determine the allele frequencies of the indels or of a
SNP at (−787) upstream of exon 1.7. We also could not determine the genotype of an indel
and VNTR (variable number of tandem repeats) in intron 4 that were reported previously.
While using the 60 CA DNA samples to resequence the additional regions that were not covered
in our previous study (18), we identified 11 additional SNPs in Caucasians in addition to the
original 37 SNPs identified during our previous study (Figure 1, Supplementary Table 4). Four
SNPs, including the A383G that resulted in a 128His>Arg amino acid alteration, were observed
only in breast tissue, including both normal and tumor tissue (Figure 1 and Supplementary
Table 4).
Functional characterization of His128Arg
Since the His128Arg was only observed in breast tumor and normal breast germline DNA at
a 1% allele frequency and had not been observed in the 60 Caucasian subjects included in our
previous resequencing study, we performed functional genomic studies with that SNP.
Microsomal preparations from COS-1 cells transiently transfected with WT, Arg128 and empty
vector were used to perform enzyme assays with [1β3H] androst-4-ene-3,17-dione as substrate.
No significant difference in aromatase enzyme activity was observed between the WT and
Arg128 allozymes (Figure 2A). Substrate kinetic studies were also performed with 6 different
concentrations of [1β3H] androst-4-ene-3,17-dione, 2.5, 5, 10, 20 40 and 80nM. Representative
substrate kinetic studies for WT and Arg128 showed that apparent Km values for the WT and
Arg128 allozymes were 81 ± 4 and 164 ± 32nM, respectively. These values did not differ
significantly (P=0.08). We also performed inhibition studies with increasing concentrations of
letrozole (0.2, 0.4 and 0.8nM). Double inverse plots for the WT inhibition study with letrozole
is shown in Figure 2B. The Kis for WT was 1.6nM ± 0.11 and that for Arg128 was 1.6nM ±
0.27 (P=0.9). Western blot analysis using antibody directed against aromatase showed no
difference in expression (data not shown).
Genotype-phenotype association study
In order to identify CYP19 SNPs in breast tumor tissue that might contribute to variation in
response to AI treatment in women with ER(+) breast cancer, we performed genotype-
phenotype studies with our resequencing data using tumor DNA together with in vivo
phenotypes that had been obtained in a neoadjuvant setting, as described previously (5). DNA
samples from 45 patients were used in this analysis. Supplementary Table 1 lists the
demographic and clinical characteristics of these patients. These patients were treated with
three different AIs, with information on aromatase activity before and after AI treatment
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recorded for 45 patients and tumor size pre- and post-AI treatment for 44 patients. However,
only the 30 patients treated with letrozole and anastrozole had information on levels of E1 and
E2 pre- and post-treatment. That was because exemestane is a steroid analogue and interferes
with the assays used to measure E1 and E2 (27). As expected, most patients treated with AIs
had decreases in E1, E2 and tumor size. However, there was variation in changes in these
phenotypes before and after AI treatment (Supplementary Figure 1). Before performing the
genotype-phenotype association study, we determined the effect of the three treatments on the
phenotypes of interest. No significant differences for phenotypes were observed among drugs.
Since the effects of different AI drugs on the phenotypes were minimal, statistical analysis was
completed on the combined data for all three AIs.
Genotype-phenotype association analysis was then performed using the SNPs identified by
resequencing CYP19 in breast tumor DNA samples from 45 patients. After quality control, 27
SNPs were used in the analysis. Table 1 lists the phenotypes studied, including changes in E1,
E2, aromatase activity and tumor size as well as each of these phenotypes measured before and
after AI treatment. Two SNPs, one located at 144 bp (rs6493497) and the other located at 588
bp (rs7176005) 5’-upstream of exon 1.1, the major “placental” exon 1, were significantly
associated with change in aromatase activity before and after AI treatment (nominal P=0.0063,
P=0.039 after adjustment for multiple testing) (Table 2A and Figure 3). Specifically, those
SNPs result in greater change in aromatase activity pre- and post-AI, which indicated that
samples containing these two SNPs had greater inhibition of aromatase activity. These same
SNPs were also associated with change in E1 level (P=0.038) and with higher aromatase
activity at baseline (P=0.028), although these differences were not significant after correction
for multiple comparisons (Table 2A). Rs6493497 and rs7176005 were in LD (R2=1), with
observed MAFs of 17% in these samples (Supplementary Figure 2). Another two linked SNPs
(R2=1), one located (−690) and the other (−725) upstream of exon 1.f, were significantly
associated with post-drug aromatase activity, with P=0.022 adjusted for multiple testing.
Marginally, the SNP at (−628) upstream of 5'-FR for exon 1.5 was also associated with change
in aromatase (P=0.06 after adjustment for multiple testing). We also performed haplotype
analysis using the resequenced SNPs, but none of the haplotypes showed a significant
association with the phenotypes of interest after correction for multiple testing (data not
shown).
Since rs6493497 and rs7176005 were associated with multiple phenotypes that were related
to aromatase activity and aromatase inhibition, we also performed a follow-up study by
genotyping these two SNPs using an additional 200 DNA samples isolated from post-
menopausal women with breast cancer who were treated with 1.0 mg anastrozole per day in
the adjuvant setting. Plasma samples had been collected before and after the initiation of
anastrozole treatment for the measurement of E1 and E2 levels as well as plasma anastrozole
concentrations, although tissue aromatase enzyme activity was not available for these patients.
The MAFs for rs6493497 and rs7176005 were 12% and 13%, respectively, in these 200
samples. The genotype-phenotype association study for these 200 subjects was performed
using levels of E1, E2 and change in E1 and E2 before and after anastrozole as phenotypes.
Both SNPs were significantly associated with pre- (P=0.028 for rs6493497 and 0.057 for
rs7176005) and post-drug E2 (P=0.0002 for both SNPs) concentrations after adjustment for
plasma anastrozole concentration (Table 2B). The average plasma concentration of anastrozole
in these 200 subjects was 32.2 ng/ml, with a range from 0.0 to 98.8 ng/ml. Specifically, with
each added minor allele, rs6493497 and rs7176005 were associated with 13- and 11-fold
increases in post-drug E2 level, respectively. We will discuss the possible implications of the
genotype-phenotype association results in the Discussion.
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Functional characterization of rs6493497 and rs7176005
To further understand the functional effect of the two significant SNPs located in the 5’-FR of
CYP19 exon1.1, we performed a series of functional genomic studies. These SNPs are located
in the major “placental” promoter, exon1.1, so we first attempted to determine whether this
exon was expressed in breast tumor tissue using exon array data obtained with seven RNA
samples isolated from breast tumor tissue, a subset of the tumor samples included in this study.
Figure 4A shows these exon array data and indicates that, although the expression of this exon
in breast tumor tissue was low, as shown by the arrow, it was clearly expressed. We then
performed EMSA to test for possible DNA-protein binding within the regions containing these
two SNPs using nuclear extract from the SKBR03 cells. SKBR03 cells have WT sequence for
both of these SNPs (Figure 4B). We chose this cell line since a previous study performed by
Kinoshita and Chen demonstrated that aromatase is highly expressed in these cells and that
estrogen can upregulate aromatase expression through CYP19 promoter 1.1 (28). EMSA
showed that the WT sequence at position (−588) displayed greater DNA-protein binding than
did the variant sequence. This effect was less striking for the SNP at position (−144), although
binding for the WT sequence was slightly stronger than for the variant (Figure 4B). Reporter
gene assay indicated that the AT and AC combinations both displayed increased transcription
activity, with AC having the most significant effect (Figure 4C), i.e., that the effect on
transcription was most striking for the (−144) SNP. The TC combination had not been observed
in any of the patients. Therefore, we did not study that haplotype.
Discussion
Breast cancer remains the most common cancer among women, and the majority of post-
menopausal women have tumors that are ER(+) and, as a result, are candidates for endocrine
therapy (29). Over the past decade, AIs have become established in both the metastatic and
adjuvant settings and are a main focus of research in the prevention setting in post-menopausal
women at high risk of developing breast cancer (3,4,30). Aromatase (CYP19) catalyzes the
conversion of androgens to estrone (E1) or estradiol (E2) (31). Therefore, inhibition of
aromatase has become a mainstream treatment of post-menopausal women with ER(+) breast
cancer. Third generation aromatase inhibitors (AIs) include the steroid derivative, exemestane,
and the nonsteroidal agents, letrozole and anastrozole. However, response to treatment with
these drugs varies widely, ranging from lack of efficacy to severe side effects (32,33). One
possible explanation is that genetic variation in the genes encoding the drug target, or drug-
metabolizing enzymes, might contribute to this variation in response. Previous resequencing
studies of CYP19, identified 88 SNPs using 240 ethnically-defined germline DNA samples
(18). In the current study, we expanded our previous resequencing effort to include DNA
isolated from breast tumor and normal tissue to test the hypothesis that genetic variation in
CYP19 might play an important role in variation in aromatase enzyme activity, estrogen
production and clinical response. Our study took advantage of a unique sample set collected
at the University of Edinburgh (5). These samples were collected in a neoadjuvant setting, with
information on in vivo E1 and E2 levels, aromatase activity in the tumor and tumor size pre-
and post-AI treatment.
Resequencing of CYP19 in these samples identified a total of 48 SNPs, including 4 novel SNPs
as compared with previous resequencing efforts (Figure 1 and Supplementary Table 4).
Functional characterization of a novel nonsynonymous cSNP, Arg128, failed to show an effect
on aromatase enzyme activity, apparent Km value or Ki values with letrozole (Figure 2).
However, genotype-phenotype association studies performed using 27 SNPs identified during
resequencing with in vivo and clinical data for 45 patients as phenotypes, identified two tightly
linked SNPs, rs6493497 and rs7176005, that were significantly associated with a greater
change in aromatase activity before and after AI treatment (Table 2A and Figure 3), with
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adjusted P values=0.038 for both SNPs. These same SNPs were also moderately associated
with change in E1 level and with baseline aromatase activity in these tumor samples. These
two SNPs were associated with higher basal aromatase activity, compatible with the results of
our luciferase reporter gene assay which showed high activity for the variant SNPs, as well as
greater inhibitory effect of AIs, which might be due to the elevated baseline level of aromatase
activity (Figure 3 and Figure 4B and C). However, these two SNPs were not associated with
levels of either E1 or E2 pre- or post-AI treatment in tumor tissue, which could be due to the
small sample size since E1 and E2 levels were only available for the 30 samples from patients
treated with letrozole or anastrozole.
We next performed a follow-up study with an additional 200 DNA samples obtained from
women with breast cancer who had been treated with 1.0mg anastrozole. We had measured
plasma E1 and E2 concentrations as well as anastrozole levels in these patients before and after
AI treatment. These phenotypes were used to perform a genotype-phenotype correlation study
to determine whether the two SNPs identified in the Edinburgh patients might be associated
with plasma estrogen concentrations. Although the samples in the follow-up study were
germline DNA, we hypothesized that, if the SNPs had functional effects on aromatase activity
and inhibition by AIs, they might have similar effects on plasma estrogen levels. We performed
the follow-up study with the two SNPs independently in order to avoid multiple comparisons,
since they were tightly linked. The results showed that both SNPs were significantly associated
with plasma E2 level before and after anastrozole treatment (Table 2B), adjusted for plasma
drug concentrations, a potential confounding variable. We observed this association only with
E2 and not E1, which might be due to different precursors for E1 and E2, with E1 being formed
from androstenedione and E2 from testosterone. Both SNPs were associated with higher E2
levels, particularly after treatment with anastrozole (Table 2B), which could be related to our
observations with the tumor DNA in which the two SNPs were moderately associated with
higher aromatase activity at baseline. Although inhibition was greater with samples harboring
these SNPs in tumor tissue (Figure 3), this might not result in lower estrogen levels after AI
treatment because of the higher basal aromatase activity for samples with these two SNPs.
We next determined how these two SNPs might affect aromatase function. We performed
reporter gene and EMS assays which demonstrated that the two SNPs showed different DNA
protein binding patterns for WT and variant sequences – particularly for the (−588) SNP – and
that they displayed different transcriptional activity when compared with the WT sequence
(Figure 4B and C). These functional studies provided additional evidence that these SNPs
might result in increased aromatase transcription and, thus, higher aromatase activity, resulting
in higher estrogen production even though the inhibition of aromatase activity was greater in
the presence of the SNPs, which might be due to the higher aromatase expression (more drug
target for AIs). It would be interesting to determine whether tumor samples containing these
SNPs have different CYP19 expression than WT. However, because the quantity of tumor
tissue was very limited, we were unable to test that hypothesis. This possibility should be tested
in future studies. We did not observe an association with tumor size or change in tumor size
before and after AIs, nor did we observe an association with E1 or E2 pre- and post-AI treatment
in tumors, which might be due to the small sample size studied. However, the fact that
rs6493497 and rs7176005 in the 5’-FR of exon 1.1 of CYP19 were associated with aromatase
activity and also displayed an association with plasma E2 levels before and after AI treatment
suggests an important functional role for these two SNPs in variation in response to AI therapy.
It also raises the possibility that these same SNPs might play a role in risk for breast cancer,
since estrogen is a major risk for breast cancer. All of these possibilities need to be tested further
in further larger independent patient cohorts.
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Figure 1.
Human CYP19 gene structure and polymorphisms. The figure shows a schematic
representation of the human CYP19 gene. Exons are represented as rectangles, with black
rectangles indicating the open reading frame (ORF) and white indicating untranslated regions
(UTRs). Arrows indicate the locations of polymorphisms, with colors representing minor allele
frequencies. Red arrows indicate polymorphisms with frequencies of >10%, while blue and
black arrows indicate polymorphisms with frequencies from 1% to 10% and of <1%,
respectively. “*” represents SNPs that were “novel” to this study.
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Figure 2.
Functional characterization of the CYP19 Arg128 variant allozyme. (A). Enzyme activity
assay. CYP19 enzyme activity was measured with microsomal preparations from cells
transfected with “empty” vector, WT and Arg128 constructs using [1β3H] androst-4-ene-3,17-
dione as substrate. Error bars are mean ± SEM for 3 independent experiments. (B).
Representative letrozole inhibition study of WT CYP19. Double inverse plots were created
using 6 concentrations of [1β3H] androst-4-ene-3,17-dione in the presence of increasing
concentrations of letrozole (0-0.8nM).
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Figure 3.
Genotype-phenotype association study. Quartile box plot was plotted between the genotypes
of the two SNPs, rs6493497 (−588) and rs7176005 (−144), and change in aromatase activity
measured in tumor tissue pre- and post-AI treatment.
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Figure 4.
Functional characterization of CYP19 rs6493497 (−588) and rs7176005 (−144). (A) Exon array
analysis of CYP19 expression in 7 breast tumor samples. Exon array probe sets (1-30) for
CYP19 are plotted against expression levels. The arrow indicates probe sets for exon 1.1. The
red rectangular box indicates the coding region of the gene. The cutoff for the expression level
is 3. (B) EMSA of SNPs at (−588) and (−144) upstream of exon 1.1. EMSA were performed
using biotin-labeled probes containing WT or variant sequences using nuclear extract from
SKBR03 Cells. Competition reactions were performed with 400-fold excess of unlabeled
probes. (C) Reporter gene assays. Reporter gene constructs were created for WT (GC) and the
observed haplotypes (AT and AC) for the rs6493497 and rs7176005 SNPs. Luciferase activity
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was corrected for Renilla luciferase activity and is expressed as a percent of the WT activity.
Values are mean ± SEM for 3 independent experiments.
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Table 1
Summary of clinical and in vivo phenotypes for breast cancer patients. These phenotypes were determined as
part of a previous study (5).
Phenotype Pre-treatment Post-treatment Post-Pre
Tumor volume
    N 44 44 44
    Mean (SD) 8.5 (11.00) 2.2 (2.38) −6.4 (9.08)
Aromatase activity (fmol/
mg protein/h)
    N 45 45 45
    Mean (SD) 33.9 (41.80) 6.1 (13.16) −27.8 (40.71)
    Median 23.0 0.0 −21.0
E1 Level (dpm/g)
    N 30 30 30
    Mean (SD) 1.9 (2.79) 0.4 (0.40) −1.5 (2.73)
    Median 0.7 0.3 −0.5
E2 Level (dpm/g)
    N 30 30 30
    Mean (SD) 1.5 (1.27) 0.3 (0.34) −1.2 (1.25)
    Median 1.2 0.3 −0.8
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Table 2A
Results of genotype-phenotype correlation study for rs7176005 and rs6493497.
Phenotype Marker Pearson r Unadjusted P-value Adjusted P-value
Change in aromatase activity 5'-FR of
Exon 1.2
(−588)
rs7176005
−0.40 0.006 0.039
  5'FR of
Exon 1.1
(−144)
rs6493497
−0.40 0.006 0.039
Change in E1 5'-FR of
Exon 1.2
(−588)
rs7176005
−038 0.038 0.180
  5'FR of
Exon 1.1
(−144)
rs6493497
−0.38 0.038 0.180
Pre-treatment aromastase activity 5'-FR of
Exon 1.2
(−588)
rs7176005
0.33 0.028 0.151
5'FR of
Exon 1.1
(−144)
rs6493497
0.33 0.028 0.151
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